CancerPal-CyclesNCT06259136
Palliative Care Yields Cancer Wellbeing Support
A study testing A transitional palliative care intervention in people with Cancer, run by Radboud University Medical Center at 1 site in Netherlands.
Trial summary
The goal of this study is to evaluate the effectiveness of a programme for transitional palliative cancer care (Pal-Cycles) in seven countries (the Netherlands, Germany, United Kingdom, Hungary, Poland, Romania and Portugal) and its consequent effects on the number of readmissions into hospital. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- A transitional palliative care intervention
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,050 participants
- Where
- 1 siteNetherlands
- Study dates
- 1 Jun 2024to Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged 18 years or above
- Patients diagnosed with advanced cancer
- Patients that are expected to develop or already may have palliative care needs
- Patients who are in transition from curative (hospital) to palliative care (community care)
Who cannot join
- People with cancer unable or unwilling to provide consent to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Netherlands1 site, 1 recruiting
- Recruiting
Radboudumc
Nijmegen, Gelderland, 6525GA
Pippa J. van den Brand, Msc, +31 0643478851, pippa.vandenbrand@radboudumc.nl
Ian Koper, PhD, ian.koper@radboudumc.nl
About this study
The goal of this study is to evaluate the effectiveness of a programme for transitional palliative cancer care (Pal-Cycles) in seven countries (the Netherlands, Germany, United Kingdom, Hungary, Poland, Romania and Portugal) and its consequent effects on the number of readmissions into hospital.
The main hypothesis for the study is: that fewer people in the intervention arm of the study will require hospital re admission than those having usual care.
Participants will be asked to fill in questionnaires regarding their quality of care and quality of life.
Read the detailed description
The study described in this protocol, a stepped wedge clinical trial, is part of a larger research project named: The Palliative Care Yields Cancer Wellbeing Support Programme (Pal-Cycles). The aim is to test and evaluate the implementation of the Pal-Cycles intervention, by implementing it in 14 care setting across seven European countries (the Netherlands, Germany, United Kingdom, Poland, Hungary, Romania and Portugal.) The primary focus of the evaluation will be on measuring the effect of the Pal Cycles intervention using the number of patients being readmitted into hospital after they had transferred to community care in comparison with patients receiving usual care. Additional relevant outcomes will also be gathered and analysed such as: the patient's quality of life, the experience from the family carer and the experience from the healthcare professional. Finally, an economic analysis will be embedded in the stepped wedge design.
The goals of the overarching research project are as follows:
- To develop, implement and evaluate a transitional palliative cancer care intervention, with an intervention (the Pal-Cycles intervention) that aims for a smooth transition from the hospital to community-based care in the final months of life.
- Adaptation of the transitional palliative cancer care intervention for patients with advanced cancer for its implementation in seven European countries within the project.
- Training of oncologists in identifying patients with palliative care needs, establishing collaboratively comprehensive treatment and care plans, delivering patient-centred communication around discharge planning, advance care planning, and end-of-life care.
- A clinical trial using a stepped wedge design will be implemented in fourteen care settingsacross seven European countries.
- An implementation support intervention will guide the implementation of the clinical trial in all settings and will investigate barriers and opportunities for implementation and provide tailormade solutions where needed.
- Dissemination of project results.
- Conditions
- Cancer
- Being tested
- A transitional palliative care intervention
- Keywords
- Palliative care, Transitional care, End of life care
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
A transitional palliative care interventionProcedure or surgery
Also called Pal-Cycles intervention
The Pal-Cycles intervention starts just before the care transition from curative oncology care to palliative care with a goals of care conversation between a hospital care provider and the patient. The conversation will be recorded in a summary of treatment and care form which will be completed by a hospital based clinician based on the key elements of the conversation with the patient and the treatment and care plan. Afterwards a (digital) copy of the form is given to the patient and another copy is sent to the general practitioner in combination with the discharge letter.
| Study group | Role | What they receive |
|---|---|---|
| Pal-Cycles Intervention | Experimental | The patients in the intervention arm will be exposed to the Pal-Cycles intervention. Receives: Procedure: A transitional palliative care intervention |
| Care as usual | No intervention | The patients included in this intervention will be given care as usual. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The difference in number of readmissions into hospital between the patients in the intervention arm and controle arm
The primary outcome of this research project will be the difference between the readmission rate from the control group and the intervention group. This was chosen based on the presumption that if the communication between healthcare professionals improves, the transition to home will be better and patients will be less likely to require hospital care. Another advantage is that it is a feasible and often well documented outcome measure which can be retrieved across multiple sites in multiple countries. A second advantage especially relevant for studies concerned with palliative care patients is that it can be measured early, as many patients die (of unrelated causes) during the study. By measuring early measurement compliance can be ensured.
Measured: 90 days after the end of the study or after death.
Secondary outcomes (11)
Demographic characteristics relative
In order to gain some background on which relative is filling in the FAMCARE, the relative will also be asked some demographic questions concerning their age, gender and relationship to patient.
Measured: 14 days after baseline.
European Organization for Research and Treatment for Cancer Quality of Life Questionnaire C30
In addition to the number of admissions, another important indicator for the effectiveness of the Pal-Cycles interventions is the quality of life of life. To measure this multiple questionnaires will be used. One of them being the EORTC QLQ-C30. The questionnaire comprises of 30 questions assessing the patients ability to function from a physical, emotional, cognitive and functional point of view. For 28 of the questions the response can be given via a four point Likert scale giving the options: not at all, a little, quite a bit, very much. Where 1, not at all, indicates a higher score than 4, very much. The last two questions can be responded to via a visual analogue scale from 1 to7 (poor to excellent). Where 7, excellent, indicates a higher score than than 1, poor.
Measured: Baseline, 30 days and 90 days after baseline.
The Functional Assessment of Cancer Therapy - General (FACT-G)
The other questionnaire that will be used to measure the patients quality of life is the FACT-G. The FACT-G was specifically developed to measure the cancer patient's health-related quality of life. This questionnaire for current and former cancer patients, is made up of 27 questions regarding quality of life by assessing wellbeing in four domains: physical, emotional, cognitive and functional. To all questions can be responded by filling in a 5 point likert scale; not at all, a little bit, somewhat, quite a bit and very much. Where 0, not at all, indicates a better score than 4, very much.
Measured: Baseline, 30 days and 90 days after baseline.
The Consultation and Rational Empathy measure (The CARE measure)
Another important outcome measure for this study is whether or not the Pal-Cycles intervention improves the quality of care. A key part of the Pal-Cycles intervention is the conversation between the clinician and the patient where the transition from curative oncological care to palliative care is discussed. To evaluate this conversation the CARE measure was included in the study. This questionnaire consists of ten Likert scale questions in which the emotional, ethical, cognitive and behavioural elements of the consultation.
The patients can respond to the questionnaire by using a five point Likert scale consisting of the following options: 1 poor,2 fair, good,3 very good, 4 excellent. Where 4 excellent is indicating a better conversation than 3 very good.
Measured: 14 days after baseline
Caregiver Network Analysis
The Caregiver Network Analysis was developed based on existing literature during a previous European project Insup-c for the purposes of a care network analysis. In the current project the objective is to improve the transition from curative care at the hospital to palliative care at home by ameliorating the communication between healthcare professionals. The questionnaire could assist in establishing if this is effective. The caregiver network analysis consists of twelve questions about which healthcare providers the patient has contact with as well as how the patient perceives their level of cooperation and quality of care. The answer options vary from dichotomous answer categories and open ended answers to 5- point Likert scales which have a range from 0 to 4. Where 4 , strongly agree, indicates a better score than 0 strongly disagree.
Measured: 30 days after baseline
FAMCARE
Family carers play a large role in caring for patients with palliative care needs. There is an international trend to reduce hospital admission days and stimulate, community care, in order to decrease healthcare costs, but also to empower patients and their families. Therefore, measuring the family satisfaction with care has become integral to evaluating the quality of care. A scale that has proven to be a reliable measurement instrument is the FAMCARE. It was developed to measure satisfaction on performance of individual care takers performance of family members of patients with advanced cancer. This questionnaire consists of 20 questions to which can be responded to by a five point Likert scale. Where 1, very satisfied, indicates a better score than 5, very dissatisfied.
Measured: 14 days after baseline
Place and date of death
Measured: 90 days after the end of the study or after death.
Presence of Advance decisions to refuse treatment (ADRTs) and Advance care plans (ACPs) as referred to in the hospital medical records.
Measured: 90 days after the end of the study or after death.
Referrals to palliative care services
Measured: 90 days after the end of the study or after death.
Economic analysis to assess the consequences of the intervention on health outcomes and resource utilization
Measured: 90 days after the end of the study or after death.
Demographic characteristics patients
The demographic characteristics of the patient will be asked in a questionnaire. In addition to participating in the stepped wedge clinical trial described in this research protocol, they are also the co-lead on work package 5. This work package has as objective to analyse whether certain "sensitive" characteristics have influenced the quality of care of the patient during the oncology treatment. To limit patient burden the demographic characteristics in the questionnaire such as gender, age, civil status and members of the household will also be used as background information for the stepped wedge clinical trial.
Measured: Baseline.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2024
- Study start1 Jun 2024
- Primary completionOct 2026 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Single group
- Model description
- For this study a cross-sectional stepped wedge clustered clinical trial will be conducted. The design will start by an initial period in which all clusters e.g. different hospital sites, are part of the control group in which the patients receive care as usual. Subsequently, groups of clusters are exposed to the intervention at regular intervals (steps) until all clusters patients in all clusters have received care as defined in the intervention. The decision about which group of clusters will receive the intervention at which point in time is decided by randomization
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 1,050 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Radboud University Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Lancaster University, University Hospital, Bonn, University of Navarra, University in Zielona Góra, University of Pecs, European Association for Palliative Care, Universidade Católica Portuguesa, Hospice Villa Speranza
- Responsible party
- Sponsor
- Investigators
- Jeroen Hasselaar, Principal investigator, Radboud University Medical Center (Radboudumc)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06259136
- Sponsor's protocol ID
- 101057243
- Acronym
- Pal-Cycles
- Status last verified
- Mar 2025
- First submitted
- 6 Feb 2024
- Last updated
- 28 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: For WP3 the final dataset will be registered and deposited at the certified DANS-EASY archive. The data will be described with rich metadata in the English language.
Publications
Hooley R, Payne S, Brunsch H, Surges SM, Mosoiu D, Hurducas F, Hernandez-Marrero P, Pereira SM, Csikos A, Pozsgai E, Leppert W, Forycka-Ast M, van den Brand P, Hasselaar J, Preston N. Adapting a palliative care intervention for people with advanced cancer across seven European countries: the Pal-Cycles intervention. BMC Palliat Care. 2026 Jun 12;25(1):181. doi: 10.1186/s12904-026-02105-0.
PubMed 42332712
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Palliative Care Yields Cancer Wellbeing Support
- ClinicalTrials.gov ID
- NCT06259136
- Acronym / sponsor ID
- Pal-Cycles / 101057243
- Conditions
- Cancer
- Keywords
- Palliative care, Transitional care, End of life care
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,050 participants (estimated)
- Lead sponsor
- Radboud University Medical CenterUniversity, hospital or other
- Collaborators
- Lancaster University, University Hospital, Bonn, University of Navarra, University in Zielona Góra, University of Pecs, European Association for Palliative Care, Universidade Católica Portuguesa, Hospice Villa Speranza
- Study start
- 1 Jun 2024 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 14 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to evaluate the effectiveness of a programme for transitional palliative cancer care (Pal-Cycles) in seven countries (the Netherlands, Germany, United Kingdom, Hungary, Poland, Romania and Portugal) and its consequent effects on the number of readmissions into hospital.
The main hypothesis for the study is: that fewer people in the intervention arm of the study will require hospital re admission than those having usual care.
Participants will be asked to fill in questionnaires regarding their quality of care and quality of life.
Detailed description
The study described in this protocol, a stepped wedge clinical trial, is part of a larger research project named: The Palliative Care Yields Cancer Wellbeing Support Programme (Pal-Cycles). The aim is to test and evaluate the implementation of the Pal-Cycles intervention, by implementing it in 14 care setting across seven European countries (the Netherlands, Germany, United Kingdom, Poland, Hungary, Romania and Portugal.) The primary focus of the evaluation will be on measuring the effect of the Pal Cycles intervention using the number of patients being readmitted into hospital after they had transferred to community care in comparison with patients receiving usual care. Additional relevant outcomes will also be gathered and analysed such as: the patient's quality of life, the experience from the family carer and the experience from the healthcare professional. Finally, an economic analysis will be embedded in the stepped wedge design.
The goals of the overarching research project are as follows:
- To develop, implement and evaluate a transitional palliative cancer care intervention, with an intervention (the Pal-Cycles intervention) that aims for a smooth transition from the hospital to community-based care in the final months of life.
- Adaptation of the transitional palliative cancer care intervention for patients with advanced cancer for its implementation in seven European countries within the project.
- Training of oncologists in identifying patients with palliative care needs, establishing collaboratively comprehensive treatment and care plans, delivering patient-centred communication around discharge planning, advance care planning, and end-of-life care.
- A clinical trial using a stepped wedge design will be implemented in fourteen care settingsacross seven European countries.
- An implementation support intervention will guide the implementation of the clinical trial in all settings and will investigate barriers and opportunities for implementation and provide tailormade solutions where needed.
- Dissemination of project results.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- For this study a cross-sectional stepped wedge clustered clinical trial will be conducted. The design will start by an initial period in which all clusters e.g. different hospital sites, are part of the control group in which the patients receive care as usual. Subsequently, groups of clusters are exposed to the intervention at regular intervals (steps) until all clusters patients in all clusters have received care as defined in the intervention. The decision about which group of clusters will receive the intervention at which point in time is decided by randomization
| Arm | Type | Receives |
|---|---|---|
| Pal-Cycles Intervention | Experimental | Procedure: A transitional palliative care interventionThe patients in the intervention arm will be exposed to the Pal-Cycles intervention. |
| Care as usual | No intervention | –The patients included in this intervention will be given care as usual. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients aged 18 years or above
- Patients diagnosed with advanced cancer
- Patients that are expected to develop or already may have palliative care needs
- Patients who are in transition from curative (hospital) to palliative care (community care)
Key exclusion criteria (1 listed)
- People with cancer unable or unwilling to provide consent to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| A transitional palliative care interventionAlso: Pal-Cycles interventionThe Pal-Cycles intervention starts just before the care transition from curative oncology care to palliative care with a goals of care conversation between a hospital care provider and the patient. The conversation will be recorded in a summary of treatment and care form which will be completed by a hospital based clinician based on the key elements of the conversation with the patient and the treatment and care plan. Afterwards a (digital) copy of the form is given to the patient and another copy is sent to the general practitioner in combination with the discharge letter. | Procedure or surgery | Pal-Cycles Intervention |
Primary outcome
The difference in number of readmissions into hospital between the patients in the intervention arm and controle arm
Time frame: 90 days after the end of the study or after death.
The primary outcome of this research project will be the difference between the readmission rate from the control group and the intervention group. This was chosen based on the presumption that if the communication between healthcare professionals improves, the transition to home will be better and patients will be less likely to require hospital care. Another advantage is that it is a feasible and often well documented outcome measure which can be retrieved across multiple sites in multiple countries. A second advantage especially relevant for studies concerned with palliative care patients is that it can be measured early, as many patients die (of unrelated causes) during the study. By measuring early measurement compliance can be ensured.
11 secondary outcomes
Demographic characteristics relative
Time frame: 14 days after baseline.
European Organization for Research and Treatment for Cancer Quality of Life Questionnaire C30
Time frame: Baseline, 30 days and 90 days after baseline.
The Functional Assessment of Cancer Therapy - General (FACT-G)
Time frame: Baseline, 30 days and 90 days after baseline.
The Consultation and Rational Empathy measure (The CARE measure)
Time frame: 14 days after baseline
Caregiver Network Analysis
Time frame: 30 days after baseline
FAMCARE
Time frame: 14 days after baseline
Place and date of death
Time frame: 90 days after the end of the study or after death.
Presence of Advance decisions to refuse treatment (ADRTs) and Advance care plans (ACPs) as referred to in the hospital medical records.
Time frame: 90 days after the end of the study or after death.
Referrals to palliative care services
Time frame: 90 days after the end of the study or after death.
Economic analysis to assess the consequences of the intervention on health outcomes and resource utilization
Time frame: 90 days after the end of the study or after death.
Demographic characteristics patients
Time frame: Baseline.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2025.
- Derived from this study: PubMed 42332712Hooley R, Payne S, Brunsch H, Surges SM, Mosoiu D, Hurducas F, Hernandez-Marrero P, Pereira SM, Csikos A, Pozsgai E, Leppert W, Forycka-Ast M, van den Brand P, Hasselaar J, Preston N. Adapting a palliative care intervention for people with advanced cancer across seven European countries: the Pal-Cycles intervention. BMC Palliat Care. 2026 Jun 12;25(1):181. doi: 10.1186/s12904-026-02105-0.
- Individual participant dataSharing planned: Yes. For WP3 the final dataset will be registered and deposited at the certified DANS-EASY archive. The data will be described with rich metadata in the English language.
Related trials for Cancer
RecruitingPhase 2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Not yet recruiting
Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
Breast Cancer Screening, Breast Cancer Awareness
Not yet recruiting
The AYA Oncology Self-care Movement
Acute Lymphobkastic Leukemia, Medication Adherence
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingPhase 2
The COSMYC Trial (COmbined Suppression of MYC)
Metastatic Castration-resistant Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jeroen Hasselaar principal investigator
Radboud University Medical Center (Radboudumc)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing A transitional palliative care intervention in people with Cancer, run by Radboud University Medical Center at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pippa van den Brand, MSC (024 361 1111, pippa.vandenbrand@radboudumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The difference in number of readmissions into hospital between the patients in the intervention arm and controle arm (time frame: 90 days after the end of the study or after death.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06259136, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2025.